ATE385796T1 - N-aryl-piperidin-substituierte biphenylcarboxamide als hemmer der sekretion von apolipoprotein b - Google Patents

N-aryl-piperidin-substituierte biphenylcarboxamide als hemmer der sekretion von apolipoprotein b

Info

Publication number
ATE385796T1
ATE385796T1 AT03792260T AT03792260T ATE385796T1 AT E385796 T1 ATE385796 T1 AT E385796T1 AT 03792260 T AT03792260 T AT 03792260T AT 03792260 T AT03792260 T AT 03792260T AT E385796 T1 ATE385796 T1 AT E385796T1
Authority
AT
Austria
Prior art keywords
inhibiters
apolipoprotein
piperidine
secretion
aryl
Prior art date
Application number
AT03792260T
Other languages
English (en)
Inventor
Lieven Meerpoel
Leo Backx
Peter Roevens
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE385796T1 publication Critical patent/ATE385796T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03792260T 2002-08-12 2003-08-05 N-aryl-piperidin-substituierte biphenylcarboxamide als hemmer der sekretion von apolipoprotein b ATE385796T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02078309 2002-08-12

Publications (1)

Publication Number Publication Date
ATE385796T1 true ATE385796T1 (de) 2008-03-15

Family

ID=31896911

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03792260T ATE385796T1 (de) 2002-08-12 2003-08-05 N-aryl-piperidin-substituierte biphenylcarboxamide als hemmer der sekretion von apolipoprotein b

Country Status (31)

Country Link
US (2) US20060040989A1 (de)
EP (1) EP1536796B1 (de)
JP (1) JP4559856B2 (de)
KR (1) KR101052204B1 (de)
CN (3) CN101165052B (de)
AR (1) AR040968A1 (de)
AT (1) ATE385796T1 (de)
AU (1) AU2003250215B2 (de)
BR (1) BR0313377A (de)
CA (1) CA2494208C (de)
CY (1) CY1107945T1 (de)
DE (1) DE60319097T2 (de)
DK (1) DK1536796T3 (de)
EA (1) EA008061B1 (de)
EG (1) EG25699A (de)
ES (1) ES2301873T3 (de)
HR (1) HRP20050103B1 (de)
IL (1) IL166795A (de)
IS (1) IS2726B (de)
MX (1) MXPA05001712A (de)
MY (1) MY136632A (de)
NO (1) NO329308B1 (de)
NZ (1) NZ538680A (de)
PA (1) PA8579901A1 (de)
PL (1) PL212405B1 (de)
PT (1) PT1536796E (de)
SI (1) SI1536796T1 (de)
TW (1) TWI342775B (de)
UA (1) UA79300C2 (de)
WO (1) WO2004017969A1 (de)
ZA (1) ZA200501225B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83510C2 (en) * 2003-12-09 2008-07-25 Янссен Фармацевтика Н.В. N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
FR2883000B1 (fr) * 2005-03-14 2007-06-01 Merck Sante Soc Par Actions Si Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EP1948629A1 (de) 2005-10-31 2008-07-30 Janssen Pharmaceutica N.V. Substituierte piperazine und piperidine als modulatoren des neuropeptid-y2-rezeptors
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
EP2261333B1 (de) * 2006-04-03 2016-03-30 Roche Innovation Center Copenhagen A/S Pharmazeutische Zusammensetzung mit Anti-miRNA-Antisense-Oligonukleotiden
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
DK2149605T3 (da) * 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
AU2008228243B2 (en) * 2007-03-22 2014-05-15 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
WO2009027527A2 (en) * 2007-08-30 2009-03-05 Santaris Pharma A/S Rna antagonist compounds for the modulation of fabp4/ap2
ES2360929T3 (es) * 2007-09-20 2011-06-10 Amgen Inc. Derivados del ácido 1-(4-(4-bencilbenzamido)-bencil)azetidin-3-carboxílico y compuestos relacionados como moduladores del receptor s1p para el tratamiento de trastornos inmunitarios.
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
EP2268811A1 (de) * 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmazeutische zusammensetzungen zur behandlung von krankheiten in verbindung mit microrna
US8492357B2 (en) 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
JP5773535B2 (ja) * 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
AU2014300981B2 (en) 2013-06-27 2017-08-10 Ricc A/S Antisense oligomers and conjugates targeting PCSK9
CA2951917C (en) 2014-06-16 2019-09-24 Johnson Matthey Public Limited Company Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4847271A (en) * 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US5041432A (en) * 1987-01-30 1991-08-20 E. I. Du Pont De Nemours And Company Steroid derivatives useful as hypocholesterolemics
US5064856A (en) * 1989-07-31 1991-11-12 Merck & Co., Inc. Novel hmg-coa synthase inhibitors
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
EP0618803A4 (de) * 1991-12-19 1995-03-22 Southwest Found Biomed Res Polypeptide als inhibitoren gegen cholesterylester-transferase, antikörper gegen die synthetischen polypeptide und prophylaktische und therapeutische behandlungsweisen der atherosklerose.
DE69332792T2 (de) 1992-04-20 2004-01-15 Takeda Chemical Industries Ltd 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
AU678503B2 (en) 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
AU3577995A (en) 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
US5510379A (en) * 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
GB9504066D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Phosphate derivatives of ureas and thioureas
WO1998047875A1 (en) * 1997-04-18 1998-10-29 Pfizer Inc. Process and intermediates for the preparation of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (1,2,3,4-tetrahydro-isoquinolin-6-yl)-amide
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
JO2390B1 (en) * 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Diphenylcarboxamides act as lipid-lowering agents
CN1233648C (zh) * 2001-06-27 2005-12-28 尔艾斯特公司 Salen催化剂、催化剂的制备和通过使用催化剂制备手性化合物的方法
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
CA2494208A1 (en) 2004-03-04
NZ538680A (en) 2006-01-27
PT1536796E (pt) 2008-05-13
KR101052204B1 (ko) 2011-07-29
WO2004017969A1 (en) 2004-03-04
SI1536796T1 (sl) 2008-08-31
AU2003250215A1 (en) 2004-03-11
ES2301873T3 (es) 2008-07-01
CN100366252C (zh) 2008-02-06
PL212405B1 (pl) 2012-09-28
NO20050563L (no) 2005-01-31
CN101165053A (zh) 2008-04-23
EA200500348A1 (ru) 2005-08-25
US20060040989A1 (en) 2006-02-23
IL166795A0 (en) 2006-01-15
AU2003250215B2 (en) 2009-01-22
IS2726B (is) 2011-03-15
HRP20050103B1 (hr) 2013-09-30
CN101165052A (zh) 2008-04-23
EG25699A (en) 2012-05-22
CY1107945T1 (el) 2013-09-04
NO329308B1 (no) 2010-09-27
US20090156623A1 (en) 2009-06-18
BR0313377A (pt) 2005-07-12
CN101165052B (zh) 2012-04-18
DE60319097T2 (de) 2009-06-04
EP1536796A1 (de) 2005-06-08
EA008061B1 (ru) 2007-02-27
UA79300C2 (en) 2007-06-11
TW200412954A (en) 2004-08-01
CN1674900A (zh) 2005-09-28
DK1536796T3 (da) 2008-06-09
AR040968A1 (es) 2005-04-27
MY136632A (en) 2008-11-28
CA2494208C (en) 2011-05-10
MXPA05001712A (es) 2005-04-19
PA8579901A1 (es) 2005-03-03
IL166795A (en) 2010-11-30
TWI342775B (en) 2011-06-01
HK1083451A1 (en) 2006-07-07
KR20050026483A (ko) 2005-03-15
IS7622A (is) 2004-12-29
ZA200501225B (en) 2006-07-26
HRP20050103A2 (en) 2006-09-30
JP4559856B2 (ja) 2010-10-13
JP2006500371A (ja) 2006-01-05
US8258304B2 (en) 2012-09-04
PL373379A1 (en) 2005-08-22
DE60319097D1 (de) 2008-03-27
EP1536796B1 (de) 2008-02-13

Similar Documents

Publication Publication Date Title
DE60321324D1 (de) Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
DE60305061D1 (de) 2-pyridonderivate als inhibitoren von neutrophiler elastase
DE60135087D1 (de) Dipeptidnitrile als inhibitoren von cathepsin k
EP1622569A4 (de) Aza-spiro-alkan-derivate als hemmer von metallproteasen
ATE348816T1 (de) 2,5-dioxoimidazolidin-4-ylacetamide und analoga als inhibitoren von metalloproteinase mmp12
ATE435211T1 (de) Imidazolidinone als ns3-serin protease inhibitoren von hepatitis c virus
DE60236226D1 (de) Verbesserung der Altersweitsichtigkeit
DE602004023080D1 (de) N-acyl stickstoffheterocyclen als liganden von peroxisom-proliferator-aktivierten rezeptoren
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DE60320529D1 (de) Chinolinderivate als npy antagonisten
DE60227686D1 (de) Mischungen von cyclosporin-analogen und ihre verwendung als immunmodulatoren
ATE370137T1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
DE60211601D1 (de) Bereitstellung von positionsabhängigen Inhalten
DE50212455D1 (de) Verwendung von Dimerdiolen
DE602005015452D1 (de) Substituierte proline als hemmer der ns3-serinprotease des hepatits-c-virus
DE602005019971D1 (de) Inhibitoren von cysteinprotease
DE60319097D1 (de) N-aryl-piperidin-substituierte biphenylcarboxamide als hemmer der sekretion von apolipoprotein b
DE02784674T1 (de) Quantifizierung von polypeptiden
DE60219068D1 (de) Substituierte 2-amino-zykloalkankarboxamide und ihre verwendung als zysteinprotease-inhibitoren
ATE427953T1 (de) Fondaparinux- natrium zusammenstellung von hoher reinheit
ATE446182T1 (de) Identifikation von modularen maschinenanbauteilen
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
ATE323081T1 (de) N-formylhydroxylamin verbindungen als inhibitoren von pdf
DE602005014646D1 (de) Substituierte propenylpiperazinderivate als neue inhibitoren von histondeacetylase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1536796

Country of ref document: EP